Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05932277 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT05932277 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 22 participants.
The verdict
NCT05932277, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of BMS-986419 on the pharmacokinetics (PK) of single doses of caffeine (CYP1A2 substrate), bupropion (CYP2B6 substrate), midazolam (CYP3A4 substrate), flurbiprofen (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and fexofenadine (P-gp substrate), in healthy participants.
Interventions
- DRUG Omeprazole
- DRUG Caffeine
- DRUG Bupropion
- DRUG Flurbiprofen
- DRUG BMS-986419
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2023-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05932277
The ClinicalTrials.gov registry entry for NCT05932277 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Omeprazole is the first listed.
NCT05932277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05932277 about?
NCT05932277 is a clinical study titled "A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants". The purpose of this study is to assess the effect of BMS-986419 on the pharmacokinetics (PK) of single doses of caffeine (CYP1A2 substrate), bupropion (CYP2B6 substrate), midazolam (CYP3A4 substrate), flurbiprofen (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and fexofenadine (P-gp substrate),...
What is the current status of trial NCT05932277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2023-06-29. Estimated completion is 2023-09-13.
What interventions are being tested in trial NCT05932277?
The interventions under investigation include: Omeprazole (DRUG), Caffeine (DRUG), Bupropion (DRUG), Flurbiprofen (DRUG), BMS-986419 (DRUG).
Who is sponsoring clinical trial NCT05932277?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.